Genfit in $228m deal with Terns Pharmaceuticals
Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor to Terns Pharmaceuticals Inc.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
Vesalius Biocapital III Fund closes at 120 million
/in News/by Thomas GabrielczykLife sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at 120m.
Erytech Pharma SA bags US$57m from SQZ Biotechnologies
/in News/by Thomas GabrielczykErytech Pharma has inked a deal with SQZ Biotechnologies Inc. to develop new immune modulating therapies.
Sanofi/Regeneron’s IL-33 blocker meets endpoint in POC study
/in News/by Thomas GabrielczykSanofis and Regenerons IL-33 blocker REGN3500 met primary Phase II endpoint in asthma patients.
Karo Pharma acquires Trimb AB
/in News/by Thomas GabrielczykKaro Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (141m).
GM proponents grill German government
/in News/by Thomas GabrielczykGerman GM proponents have taken action against discrimination of food products generated by gene editing.
IL-10R-deficient macrophages trigger IBD
/in News/by Thomas GabrielczykResearchers from Israel and the UK have identified how the cytokine IL-23 triggers inflammatory bowel syndrome (IBD), which affects 1.6 million patients annually in the US alone.
Machine learning for high-content analysis: User stories
/in News/by Thomas GabrielczykScientists from the University of Washington are using the Phenoglyphs machine learning module to achieve faster high-content analysis through automation and simplification.
Breakthrough in liquid biopsy
/in News/by Thomas GabrielczykGerman and US researchers have developed a diagnostic technique capable to detect one single circulating tumour cell in one litre of blood.
ADC Therapeutics raise $76m in Series E expansion
/in News/by Thomas GabrielczykSwiss antibody drug conjugate developer ADC Therapeutics SA raised $76m, bringing the total gross proceeds to $276 million in its Series E financing.